P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology: Durvalumab with bacillus Calmette–Guérin therapy for high-risk non-muscle-invasive bladder cancer: expanded efficacy and safety analyses from POTOMAC

P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology: Durvalumab with bacillus Calmette–Guérin therapy for high-risk non-muscle-invasive bladder cancer: expanded efficacy and safety analyses from POTOMAC

Friday, May 15, 2026 10:30 AM to 10:40 AM · 10 min. (America/New_York)
Hall D
Detail

Information

Other
Press Program

Log in

See all the content and easy-to-use features by logging in or registering!